Status:
COMPLETED
Evaluation of Vitamin K Supplementation for Calcific Uremic Arteriolopathy
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
National Kidney Foundation, United States
American Heart Association
Conditions:
Calciphylaxis
Calcific Uremic Arteriolopathy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Calcific uremic arteriolopathy a.k.a. calciphylaxis is a vascular calcification disorder seen in dialysis patients. Calcific uremic arteriolopathy has 60-80% one-year mortality and significant morbidi...
Detailed Description
Calcific uremic arteriolopathy (CUA), also known as calciphylaxis, is a vascular calcification disorder associated with 60-80% one-year mortality and significant morbidity. CUA predominantly affects e...
Eligibility Criteria
Inclusion
- Calcific uremic arteriolopathy (a.k.a. calciphylaxis)
Exclusion
- Warfarin discontinuation contra-indicated (e.g. mechanical heart valve)
- Prior allergic reaction to vitamin K
- Prior history of venous thromboembolism\*
- Pregnancy and lactation
- (\*Patients with prior history of thrombosis who are treated with non-warfarin anticoagulant agents (e.g. apixaban, enoxaparin, etc) will be considered for inclusion)
Key Trial Info
Start Date :
March 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2019
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT02278692
Start Date
March 1 2015
End Date
August 1 2019
Last Update
September 17 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114